Archimedes Pharma

archimedespharma.com

Archimedes Pharma is an international specialty pharmaceutical company providing novel and advanced treatments to address unmet needs for people living with serious or life-threatening chronic and debilitating illnesses. Marketing a diverse portfolio of specialty products focused on the oncology, pain, and critical care sectors, Archimedes Pharma has operations in Europe.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

SATIO AND INSTITUT PASTEUR DE DAKAR FORM STRATEGIC PARTNERSHIP ON RESEARCH, DEVELOPMENT, MANUFACTURE, AND DISTRIBUTION

Satio, Inc and Institut Pasteur de Dakar | August 24, 2022

news image

Satio, Inc., a privately held medical device company developing breakthrough, consumer-driven diagnostic and drug delivery solutions, announced a strategic partnership agreement with Institut Pasteur de Dakar. By combining SatioRxTM intradermal patches and Institut Pasteur de Dakar technologies, the partnership aims to accelerate clinical development of and access to vaccine patches for addressing epidemics, as well as diagnostic patches for blood sampling, genetic testing, and pa...

Read More

Business Insights

PHASEBIO PHARMACEUTICALS TO PARTICIPATE IN THE COWEN 42ND ANNUAL HEALTH CARE CONFERENCE

PhaseBio Pharmaceuticals, Inc. | February 25, 2022

news image

PhaseBio Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that Chief Executive Officer Jonathan P. Mow will participate in a panel discussion during Cowen’s 42nd Annual Health Care Conference taking place virtually on Tuesday, March 8, 2022 from 12:50 pm – 1:50 pm ET. Interested parties can access the live and archived webcasts of the virtual...

Read More

Pharmacy Market

BUSHU PHARMA'S PARTNERSHIP WITH SUZUKEN GROUP INCREASES SPECIALTY PHARMACEUTICAL SERVICES

Bushu Pharmaceuticals Ltd. | April 28, 2021

news image

Bushu Pharmaceuticals Ltd. has entered into a business partnership arrangement with Suzuken Co., Ltd. to provide specialty pharmaceutical producers looking to enter the Japanese market with extensive support for new product releases. In recent years, the market has seen an increase in the number of innovative specialty pharmaceuticals, such as biopharmaceuticals, regenerative medicines, and orphan drugs for rare diseases, that require strict temperature, inventory, and security co...

Read More

Pharma Tech

XERIS PHARMACEUTICALS ENTERS COLLABORATION AGREEMENT WITH MERCK

Xeris | October 25, 2021

news image

Xeris Biopharma Holdingsa biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced a collaboration agreement with Merck , with an option to license Xeris “We are quite excited to be working closely with Merck on this opportunity using our novel platform technology, XeriJect The XeriJect platform has broad applicability in improving the delivery of...

Read More
news image

Business Insights

SATIO AND INSTITUT PASTEUR DE DAKAR FORM STRATEGIC PARTNERSHIP ON RESEARCH, DEVELOPMENT, MANUFACTURE, AND DISTRIBUTION

Satio, Inc and Institut Pasteur de Dakar | August 24, 2022

Satio, Inc., a privately held medical device company developing breakthrough, consumer-driven diagnostic and drug delivery solutions, announced a strategic partnership agreement with Institut Pasteur de Dakar. By combining SatioRxTM intradermal patches and Institut Pasteur de Dakar technologies, the partnership aims to accelerate clinical development of and access to vaccine patches for addressing epidemics, as well as diagnostic patches for blood sampling, genetic testing, and pa...

Read More
news image

Business Insights

PHASEBIO PHARMACEUTICALS TO PARTICIPATE IN THE COWEN 42ND ANNUAL HEALTH CARE CONFERENCE

PhaseBio Pharmaceuticals, Inc. | February 25, 2022

PhaseBio Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that Chief Executive Officer Jonathan P. Mow will participate in a panel discussion during Cowen’s 42nd Annual Health Care Conference taking place virtually on Tuesday, March 8, 2022 from 12:50 pm – 1:50 pm ET. Interested parties can access the live and archived webcasts of the virtual...

Read More
news image

Pharmacy Market

BUSHU PHARMA'S PARTNERSHIP WITH SUZUKEN GROUP INCREASES SPECIALTY PHARMACEUTICAL SERVICES

Bushu Pharmaceuticals Ltd. | April 28, 2021

Bushu Pharmaceuticals Ltd. has entered into a business partnership arrangement with Suzuken Co., Ltd. to provide specialty pharmaceutical producers looking to enter the Japanese market with extensive support for new product releases. In recent years, the market has seen an increase in the number of innovative specialty pharmaceuticals, such as biopharmaceuticals, regenerative medicines, and orphan drugs for rare diseases, that require strict temperature, inventory, and security co...

Read More
news image

Pharma Tech

XERIS PHARMACEUTICALS ENTERS COLLABORATION AGREEMENT WITH MERCK

Xeris | October 25, 2021

Xeris Biopharma Holdingsa biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced a collaboration agreement with Merck , with an option to license Xeris “We are quite excited to be working closely with Merck on this opportunity using our novel platform technology, XeriJect The XeriJect platform has broad applicability in improving the delivery of...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us